ReviewFrontiers in microbiology2026
The impact of antibiotic exposure on obesity and metabolic phenotypes via the gut microbiota.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics are among the most commonly used anti-infective agents in modern medicine. However, their long-term effects on the gut microbiome have attracted increasing attention. Epidemiological studies and animal experiments in recent years suggest that antibiotic exposure can disrupt the structure and function of the gut microbiota, thereby affecting host energy metabolism, fat deposition, and immune homeostasis. Such disruptions may contribute to the development of obesity and related metabolic phenotypes. Different classes of antibiotics exert markedly distinct effects on the gut microbiota. Broad-spectrum antibiotics such as macrolides, lincosamides, and fluoroquinolones often induce more pronounced and prolonged microbial alterations, whereas the effects of certain β-lactam antibiotics appear relatively transient. Antibiotic-induced gut dysbiosis can influence host metabolism through multiple mechanisms, including reduced short-chain fatty acid production, disrupted bile acid metabolism, impaired intestinal barrier function, and chronic low-grade inflammation. These alterations may promote fat accumulation, insulin resistance, and disruption of immune homeostasis. Early-life antibiotic exposure occurs during a critical developmental window for gut microbiota maturation and may exert more profound effects on long-term metabolic health. Recent advances in multi-omics technologies have further illuminated the complex interaction network among antibiotics, the microbiome, and host metabolism. Microecological intervention strategies, such as probiotics and synbiotics, show potential for improving metabolic abnormalities associated with antibiotic-induced dysbiosis. However, their efficacy is strain-specific, and the overall effect size remains limited. This review summarizes current research progress on how antibiotic exposure influences obesity and metabolic phenotypes through the gut microbiota, outlines the underlying mechanisms, and discusses potential applications of microbiological intervention strategies. It also provides insights into antibiotic-related metabolic risks and future precision intervention approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.